新疆地区维、汉、哈族骨肉瘤患者流行病学特征分析

摘要
图/表
参考文献
相关文章 (14)

全文: PDF (568 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨新疆地区骨肉瘤流行病学特征，为临床工作提供一定参考。方法回顾2002年1月至2016年6月290例骨肉瘤患者临床病历资料，收集相关流行病学信息进行统计分析。结果新疆地区骨肉瘤年患病人数整体呈上升趋势；290例骨肉瘤患者中以维吾尔族居多，占56.6％，男女比例为1.2︰1.0，平均年龄为(24.95±16.59)岁，11～20岁为发病高峰；发病部位以膝关节周围最多见(69.7％)，病理学分型常规型骨肉瘤居多，占87.2％；首发症状以疼痛肿胀为主，占69.3％；入院伴有运动障碍者41.7％，发生病理性骨折者7.9％。民族分组分析发现各民族间性别、年龄分布，肿瘤发生部位及病理分型比较，差异无统计学意义(P＞0.05)，血清碱性磷酸酶阳性率比较，差异有统计学意义(P＜0.05)。结论维吾尔族及哈萨克族患者血清碱性磷酸酶对骨肉瘤的临床价值高于汉族及其他民族。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章

关键词 ：骨肉瘤, 流行病学, 临床特征, 新疆地区

Abstract：Objective To investigate the epidemiological characteristics of osteosarcoma in Xinjiang area and provide reference for clinical work.Methods The clinical data of 290 patients with osteosarcoma from January 2002 to June 2016 were reviewed，and related epidemiological information was collected and analyzed.Results The annual number of osteosarcoma in Xinjiang was rising.There were 290 cases of osteosarcoma patients.Uighur was 56.6％ of the total.Male to female ratio was 1.2︰1.0.The age of them were (24.95±16.59)years.11～20 years old was the peak of mobility.The most common sites was around the knee joint (69.7％)，pathological type of conventional osteosarcoma was the majority，accounting for 87.2％ of the total.The first found symptoms were pain and swelling，accounted for 69.3％.41.7％ of the patients were admitted with immobility.Pathological fractures occurred in 7.9％.Ethnic grouping analysis showed that gender，age distribution between different ethnic groups，tumor location and pathological type showed no significant difference (P＞0.05)，there was significant difference of the positive rate of serum alkaline phosphatase (P＜0.05).Conclusion The clinical value of serum alkaline phosphatase in osteosarcoma is higher than that in Han and other nationalities.

Key words： osteosarcoma epidemiology clinical characteristics Xinjiang area

基金资助:2016年新疆医科大学研究生创新创业项目(CXCY013)

通讯作者: 宋兴华

作者简介: 杨勇(1991－ )，男，研究生在读，新疆医科大学第一附属医院，830011。

引用本文:

杨勇 1，陈江涛 1，楚慧慧 2，王腾飞 1，宋兴华 *1. 新疆地区维、汉、哈族骨肉瘤患者流行病学特征分析[J]. 实用骨科杂志, 2018, 24(2): 130-133.
Yang Yong 1，Chen Jiangtao 1，Chu Huihui 2，et al. Epidemiological Features Analysis of Uighur，Han and Kazak Patients with Osteosarcoma in Xinjiang Area. sygkzz, 2018, 24(2): 130-133.

链接本文:

http://www.sygkzz.com/CN/ 或 http://www.sygkzz.com/CN/Y2018/V24/I2/130

［1］Sampo M，Koivikko M，Taskinen M，et al.Incidence，epidemiology and treatment results of osteosarcoma in finland-a nationwide population-based study［J］.Acta Oncol，2011，50(8)：1206-1214.
［2］Buckley JD，Pendergrass TW，Buckley CM，et al.Epidemiology of osteosarcoma and ewing's sarcoma in childhood：a study of 305 cases by the children's cancer group［J］.Cancer，1998，83(7)：1440-1448.
［3］Miller RW.Contrasting epidemiology of childhood osteosarcoma，ewing's tumor，and rhabdomyosarcoma［J］.National Cancer Institute Monograph，1981(56)：9-15.
［4］Mirabello L，Troisi RJ，Savage SA.Osteosarcoma incidence and survival rates from 1973 to 2004：data from the surveillance，epidemiology，and end results program［J］.Cancer，2009，115(7)：1531-1543.
［5］Bielack S，Jürgens H，Jundt G，et al.Osteosarcoma：the COSS experience［J］.Cancer Treat Res，2009(152)：289-308.
［6］Clark JC，Dass CR，Choong PF.A review of clinical and molecular prognostic factors in osteosarcoma［J］.J Cancer Res Clin Oncol，2008，134(3)：281-297.
［7］杨湘越.骨肉瘤实验室诊断研究现状和对策［J］.中华临床医师杂志，2012，6(21)：6841-6842.
［8］Ottaviani G，Jaffe N.The epidemiology of osteosarcoma［J］.Cancer Res Treat，2009(152)：3-13.
［9］张如明，卫晓恩；骨肿瘤分类的演进-2002年WHO骨肿瘤分类介绍［J].中华骨科杂志，2006，26(4)：282-285.
［10］Anninga JK，Gelderblom H，Fiocco M，et al.Chemo therapeutic adjuvant treatment for osteosarcoma：where do we stand?［J］.Euro J Cancer，2011，47(16)：2431-2445.
［11］Solooki S，Vosoughi AR，Masoomi V.Epidemiology of musculoskeletal tumors in shiraz，south of Iran［J］Indian J Med Paediatr Oncol，2011，32(4)：187-191.
［12］吴良平，刘向权，尚阳.新疆人口结构的民族差异及其问题研究——基于六普数据的分析［J］.西北人口，2015，1(36)：105-110.
［13］Lamoureux F，Terichet V，Chipoy C，et al.Recent advances in the management of osteosarcoma and forthcoming therapeutic strategies［J］.Expert Rev Anticancer Ther，2007，7(2)：169-181.
［14］Settakorn J，Rangdaeng S，Arpornchayanon O，et al.Epidemiologic study of 112 osteosarcomas in Chiang Mai University Hospital，Thailand［J］.J Med Assoc Thail，2007，90(7)：1400-1405.
［15］Cho Y，Jung GH，Chung SH，et al.Long-term survivals of stage Ⅱb osteosarcoma：a 20-year experience in a single institution［J］.Clinics in orthopedic surgery，2011，3(1)：48-54.
［16］Bramer JAM，Abudu AA，Tillman RM，et a1.Pre-and postchemotherapy alkaline phosphatase levels as prognostic indicators in adults with localized osteosarcoma［J］.Eur J Cancer，2005，41(18)：2846-2852.
［17］葛艳玲，张正.骨型碱性磷酸酶在骨肿瘤诊断中的价值［J］.中华检验医学杂志，2006，29(2)：136-139.
［18］Liu PPL，Leung KS，Lee SM，et a1.Bone-specific alkaline phosphatase in plasma as tumor marker for osteosarcoma［J］.Ontology，1996，53(4)：275-280.
［19］王京生，屠重棋，段宏等，碱性磷酸酶在骨肿瘤诊断中的价值［J］.四川大学学报(医学版)，2008，39(2)：330-331.
［20］Bielack SS，Kempf-Bielack B，Delling G，et al.Prognostic factors in high-grade osteosarcoma of the extremities or trunk：an analysis of 1 702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols［J］.J Surg Oncol，2002，20(3)：776-790.
［21］Xie L，Guo W，Li Y，et al.Pathologic fracture does not influence local recurrence and survival in high-grade extremity osteosarcoma with adequate surgical margins［J］.J Surg Oncol，2012，106(7)：820-825.
［22］Muchantef K，Pollock AN.Osteosarcoma of the lower extremity presenting as a pathologic fracture［J］.Pediatric emergency care，2012，28(9)：936-937.
［23］Mayerson JL.Limb salvage：an acceptable option in select patients with pathologic fracture in high grade osteosarcoma［J］.J Surg Oncol，2010，102(2)：119.
［24］Kim MS，Lee SY，Lee TR，et al.Prognostic effect of pathologic fracture in localized osteosarcoma：a cohort／case controlled study at a single institute［J］.J Surg Oncol，2009，100(3)：233-239.